[Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity].
Modern methods for the evaluation of drug interaction at the level of biotransformation system are discussed with special reference to the lidocaine test (MEGX) and measurement of cytochrome P-450 activity in patients with drug-induced oxidative processes in the liver. Interaction of atorvastatin with clopidogrel are shown to slightly reduce the desaggregative effect of the latter. It is concluded that MEGX test widens opportunities for personalization and safe pharmacotherapy.